Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - fenofibrate, quantity: 145 mg - tablet, film coated - excipient ingredients: docusate sodium; hypromellose; sodium lauryl sulfate; sucrose; silicified microcrystalline cellulose; crospovidone; magnesium stearate; lactose monohydrate; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenofibrate cipla is indicated as an adjunct to diet in the treatment of:,- hypercholesterolaemia;,- types ii, iii, iv and v dyslipidaemia;,- dyslipidaemia assocated with type 2 diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - fenofibrate, quantity: 48 mg - tablet - excipient ingredients: lactose; sodium lauryl sulfate; hypromellose; croscarmellose sodium; magnesium stearate; purified water; xanthan gum; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia - types ii, iii, iv and v dyslipidaemia; dyslipidaemia associated with type 2 diabetes

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - fenofibrate, quantity: 145 mg - tablet - excipient ingredients: lactose; sodium lauryl sulfate; hypromellose; croscarmellose sodium; magnesium stearate; purified water; xanthan gum; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia - types ii, iii, iv and v dyslipidaemia; dyslipidaemia associated with type 2 diabetes

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - fenofibrate, quantity: 48 mg - tablet - excipient ingredients: lactose; sodium lauryl sulfate; hypromellose; croscarmellose sodium; magnesium stearate; purified water; xanthan gum; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia - types ii, iii, iv and v dyslipidaemia; dyslipidaemia associated with type 2 diabetes

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - fenofibrate, quantity: 145 mg - tablet - excipient ingredients: lactose; sodium lauryl sulfate; hypromellose; croscarmellose sodium; magnesium stearate; purified water; xanthan gum; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia - types ii, iii, iv and v dyslipidaemia; dyslipidaemia associated with type 2 diabetes

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - fenofibrate (unii: u202363uos) (fenofibric acid - unii:bgf9mn2hu1) - fenofibrate 48 mg - fenofibrate tablets for oral use are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (ldl-c), total cholesterol (total-c), triglycerides and apolipoprotein b (apo b), and to increase high-density lipoprotein cholesterol (hdl-c) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. fenofibrate tablets for oral use are also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dl) may increase the risk of developing pancreatitis. the effect of fenofibrate therapy on reducing this risk has not been adequately studied. fenofibrate at a dose equivalent to 145 mg of fenofibrate tablets for oral use was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized con

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - fenofibrate (unii: u202363uos) (fenofibric acid - unii:bgf9mn2hu1) - fenofibrate 48 mg - fenofibrate tablets usp are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (ldl-c), total cholesterol (total-c), triglycerides and apolipoprotein b (apo b), and to increase high-density lipoprotein cholesterol (hdl-c) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. fenofibrate tablets usp are also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. markedly elevated levels of serum triglycerides (e.g., > 2,000 mg/dl) may increase the risk of developing pancreatitis. the effect of fenofibrate therapy on reducing this risk has not been adequately studied. fenofibrate at a dose equivalent to 145 mg of fenofibrate tablets usp was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of pati

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - fenofibrate (unii: u202363uos) (fenofibric acid - unii:bgf9mn2hu1) - fenofibrate 145 mg - fenofibrate tablets for oral use are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (ldl-c), total cholesterol (total-c), triglycerides and apolipoprotein b (apo b), and to increase high-density lipoprotein cholesterol (hdl-c) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. fenofibrate tablets for oral use are also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dl) may increase the risk of developing pancreatitis. the effect of fenofibrate therapy on reducing this risk has not been adequately studied. fenofibrate at a dose equivalent to 145 mg of fenofibrate tablets for oral use was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized con

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - fenofibrate, quantity: 145 mg - tablet - excipient ingredients: sodium lauryl sulfate; silicon dioxide; sucrose; pregelatinised maize starch; microcrystalline cellulose; sodium stearylfumarate; hypromellose; crospovidone; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia; - types ii, iii, iv and v dyslipidaemia; - dyslipidaemia associated with type 2 diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - fenofibrate, quantity: 48 mg - tablet - excipient ingredients: pregelatinised maize starch; hypromellose; sucrose; crospovidone; silicon dioxide; microcrystalline cellulose; sodium stearylfumarate; sodium lauryl sulfate; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia; - types ii, iii, iv and v dyslipidaemia; - dyslipidaemia associated with type 2 diabetes.